" class="no-js "lang="en-US"> David Vivero - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
David Vivero

David Vivero

About David Vivero

Internet entrepreneur with background in media, venture capital, healthcare, and real estate, and a deep interest in network effects and platform adoption, Internet marketplaces, and consumer media.

Specialties: product development, market research, software, venture capital, entrepreneurship, online business development, wireless/mobile

Related Story

Appointments

 Former Amazon

Former Amazon, Oracle Exec Greg Born Joins Amino Health as Chief Growth Officer

June 15 2022

Amino Health, the leading digital healthcare guidance platform, today announced that senior global operations executive Greg […]